Suppr超能文献

首发第一代抗精神病药物、非氯氮平第二代抗精神病药物或氯氮平出院的精神分裂症患者的再入院时间。

Time to rehospitalization in patients with schizophrenia discharged on first generation antipsychotics, non-clozapine second generation antipsychotics, or clozapine.

机构信息

Department and Institute of Psychiatry, University of Sao Paulo Medical School, Rua Dr. Ovidio Pires de Campos 785, Sao Paulo, 05403-010, Brazil.

出版信息

Psychiatry Res. 2011 Aug 15;188(3):315-9. doi: 10.1016/j.psychres.2011.04.004. Epub 2011 May 18.

Abstract

Rehospitalization is an important outcome of drug effectiveness in schizophrenia. In this study, the hypothesis that clozapine and some second generation antipsychotics (SGA) were superior to first generation antipsychotics (FGA) in preventing rehospitalization of patients with schizophrenia discharged from a university hospital in Brazil was tested. A retrospective observational study was conducted designed to evaluate time to rehospitalization of patients with schizophrenia discharged on a regimen of oral FGA, depot FGA, risperidone, olanzapine and amisulpride, other SGA, or clozapine, during a three-year follow-up period. Risk factors associated with rehospitalization were examined. Of the 464 patients with schizophrenia discharged from hospital, 242 met criteria for study entry. Higher rehospitalization rates were observed in patients treated with depot FGA (30%), risperidone (30%) and other SGA groups (28.5%), respectively. Clozapine was significantly associated with lower rehospitalization risk compared with risperidone. The risk of rehospitalization in patients on olanzapine and amisulpride, and oral FGA, was similar to that of patients in use of clozapine. These results however, are limited by the heterogeneity of illness severity across the groups.

摘要

再入院是精神分裂症药物疗效的一个重要结果。在这项研究中,我们假设氯氮平及某些第二代抗精神病药物(SGAs)优于第一代抗精神病药物(FGAs),可预防从巴西一所大学医院出院的精神分裂症患者再入院。进行了一项回顾性观察性研究,旨在评估在 3 年的随访期间,使用 FGAs 口服、长效 FGAs、利培酮、奥氮平和氨磺必利、其他 SGA 或氯氮平治疗的精神分裂症患者再入院时间。研究还检查了与再入院相关的危险因素。在出院的 464 例精神分裂症患者中,有 242 例符合研究入组标准。长效 FGAs(30%)、利培酮(30%)和其他 SGA 组(28.5%)患者的再入院率较高。与利培酮相比,氯氮平与较低的再入院风险显著相关。奥氮平和氨磺必利以及 FGAs 口服治疗的患者再入院风险与氯氮平患者相似。然而,这些结果受到各组疾病严重程度异质性的限制。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验